
Opinion|Videos|December 19, 2023
Future Perspectives and Unmet Needs in HER2+ mCRC Treatment
Drs Ciombor and Ahn discuss emerging HER2-targeted therapies in colorectal cancer, including antibody-drug conjugates and novel antibodies.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers
2
FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer
3
Lenvatinib Combo Holds Ground Against HER2 ADCs in Endometrial Cancer
4
Teclistamab Combo Earns EU Approval in Relapsed/Refractory Multiple Myeloma
5



















































